RealWorld Dynamix™: Biologic Switching in IBD

Ulcerative Colitis (UC) and Crohn’s disease (CD) are common inflammatory bowel diseases, currently affecting the lives of 1.4 million Americans. The introduction of biologics has changed the face of treatment for moderate to severe patients, and biologic switching in both UC and CD over the past 12 months is predictive of future market shape and [...]

RealTime Dynamix™: Atopic Dermatitis Q2

Atopic dermatitis, the most common form of eczema affecting 5 to 20% of the worldwide population, is a chronic inflammatory disease often presenting as a skin rash Moderate-to-severe AD is characterized by rashes often covering much of the body, and can include intense itching and dryness, crusting, redness, and oozing which can be debilitating. Until [...]

RealTime Dynamix™: Crohn’s Disease Q2

Crohn’s Disease (CD) is a common form of inflammatory bowel diseases, currently affecting the lives of approximately 700,000 Americans. Theintroduction of biologics has changed the face of treatment for moderateto-severe CD patients. However, recent launches, an active pipeline, and the imminent introduction of biosimilars present an opportunity for major future shifts in the CD landscape. [...]

RealTime Dynamix™: Psoriatic Arthritis Q2

The already highly dynamic US market for Psoriatic Arthritis (PsA) with the recent entrance of Celgene’s Otezla and Novartis’ Cosentyx is set to go up another level of complexity with Eli Lilly’s Taltz and AstraZeneca/Valeant’s brodalumab close to approval dates and line extensions being sought for Pfizer’s Xeljanz and Simponi Aria from Janssen. RealTime Dynamix: [...]

RealTime Dynamix™: Hyperkalemia (Neph) Q2

The hyperkalemia market underwent sweeping changes with the introduction of Relypsa’s Veltassa in the beginning of 2016. Veltassa represented the first new therapy for the treatment of hyperkalemia in over 50 years. In 2017, a new competitor in AstraZeneca/ZS Pharma’s ZS-9 may come into play after being delayed by a Complete Response Letter in 2016. [...]